Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256065 | 0.99 | KMT2A (0.64) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL18256060 | 0.97 | KMT2A (0.66) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL18256126 | 0.94 | KMT2A (0.69) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL20563973 | 0.82 | LMNA (0.56) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL20205938 | 0.81 | KMT2A (0.48) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL29006028 | 0.81 | KMT2A (0.66) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL9293404 | 0.81 | KMT2A (0.74) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL24559068 | 0.81 | KMT2A (0.52) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL19607724 | 0.80 | KMT2A (0.50) | KMT2AADORA2BRXFP1LMNAMAPT | |
| SCHEMBL18819581 | 0.80 | KMT2A (0.50) | KMT2AADORA2BRXFP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184312-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | KMT2A 3576/4885ADORA2B 89/4885RXFP1 1174/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | KMT2A 3576/4885ADORA2B 89/4885RXFP1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.